Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4376 |
Nampt-IN-1
LSN3154567 |
c-Fms; NAMPT; CSF-1R | Metabolism; Tyrosine Kinase/Adaptors |
Nampt-IN-1 (LSN3154567) 是选择性的 NAMPT 抑制剂,能够抑制纯化的 NAMPT,IC50=3.1 nM。 | |||
T4354 |
KPT9274
KPT-9274,KPT 9274,PAK4-IN-1 |
NAMPT; PAK | Cytoskeletal Signaling; Metabolism |
KPT9274 (PAK4-IN-1) 是一种非竞争性的 PAK4 和 NAMPT 双重抑制剂(IC50= ~120 nM)。它是一种口服生物可利用的小分子。 | |||
T61597 | Nampt-IN-7 | ||
Nampt-IN-7, also known as compound GF8, is a powerful NAMPT inhibitor exhibiting an IC50 value of 7.31 μM. It possesses significant cytotoxic effects against the human HepG2 hepatocellular carcinoma cell line, with an IC50 value of 24.28 μM [1]. | |||
T74562 | Nampt-IN-10 trihydrochloride | ||
Nampt-IN-10 trihydrochloride (compound 4) 为磷酸核糖转移酶 (NAMPT) 抑制剂。在A2780与CORL23细胞中展现出活性,IC50值依次为5和19 nM。Nampt-IN-10 trihydrochloride 同时作为抗体偶联活性分子 (ADC) 的非限制性有效载荷。 | |||
T74615 | NAMPT degrader-1 | ||
NAMPTdegrader-1 (Compound A3) 是一种酰胺磷酸核糖转移酶 (NAMPT) 降解剂,IC50为 0.023 μM。NAMPTdegrader-1 通过 autophagy-lysosomal 途径显著诱导 NAMPT 降解,表现出良好的细胞抗肿瘤能力。 | |||
T60667 |
NAT
|
||
NAT 是 NAMPT 激活剂的苗头化合物。NAMPT 是研究与 NAD 耗竭相关的许多疾病 ,例如如神经退行性疾病的有吸引力的靶点,由于其为 NAD 回收途径中的限速酶。 | |||
T18477 |
NAMPT inhibitor-linker 1
|
Others | Others |
NAMPT inhibitor-linker 1, a drug-linker conjugate for ADC, integrates an NAMPT inhibitor (as a payload) with a linker. In the formulation of ADC-3, it pairs with an anti-c-Kit monoclonal antibody, demonstrating strong efficacy against c-Kit expressing cell lines, specifically GIST-T1 and NCI-H526, where it exhibits IC50 values of <3 pM and 9 pM, respectively. | |||
T72623 | Nampt activator-3 | ||
NAMPTactivator-3 是一种 NAT 衍生物,是一种 NAMPT 激活剂,EC50为 2.6 μM,KD 为 132 nM。NAMPTactivator-3 有效保护培养细胞免受 FK866 介导的毒性。NAMPTactivator-3 在化疗引起的周围神经病变 (CIPN) 小鼠模型中表现出强大的神经保护功效,没有任何明显的毒性。 | |||
T36874 |
7-Bromoheptanoic Acid
|
||
7-Bromoheptanoic acid is a building block.1,2It has been used in the synthesis of azide-based nicotinamide phosphoribosyltransferase (Nampt) inhibitors with anticancer activity and SAHA derivatives that inhibit histone deacetylases (HDACs). 1.Colombano, G., Travelli, C., Galli, U., et al.A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistryJ. Med. Chem.53(2)616-623(2010) 2.Suzuki, T., Nagano, Y., Kouketsu, A., et al.Novel inhibitors of human histone deac... |